BIAL, a Portuguese pharma company, and Recipharm have expanded a long-term agreement for the global manufacture and supply of BIAL’s proprietary molecule opicapone. The API being manufactured at Recipharm’s facility in Cramlington, UK is used to formulate BIAL’s Ongentys product, an adjunctive therapy used to treat patients with Parkinson’s disease. The expansion of the agreement with BIAL follows the successful market authorization application in Japan, with the product launch on August...